Rep. Robert Bresnahan, Jr. Sells Zoetis Inc. (NYSE:ZTS) Stock

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Zoetis Inc. (NYSE:ZTS). In a filing disclosed on March 27th, the Representative disclosed that they had sold between $1,001 and $15,000 in Zoetis stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
• Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
• Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
• Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.

Zoetis Stock Performance

Shares of Zoetis stock opened at $163.03 on Friday. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.33. The stock has a market cap of $73.00 billion, a price-to-earnings ratio of 29.80, a PEG ratio of 2.78 and a beta of 0.94. The firm’s 50-day moving average is $166.40 and its 200 day moving average is $174.67. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.23%. Zoetis’s payout ratio is 36.56%.

Institutional Investors Weigh In On Zoetis

Hedge funds have recently added to or reduced their stakes in the company. Howard Capital Management Group LLC boosted its position in shares of Zoetis by 0.8% in the 3rd quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after buying an additional 883 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of Zoetis by 17.3% during the 3rd quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company’s stock valued at $464,497,000 after buying an additional 351,372 shares during the period. Larson Financial Group LLC lifted its stake in shares of Zoetis by 14.8% in the 3rd quarter. Larson Financial Group LLC now owns 1,588 shares of the company’s stock valued at $310,000 after purchasing an additional 205 shares in the last quarter. Harvest Fund Management Co. Ltd lifted its position in Zoetis by 237.3% during the third quarter. Harvest Fund Management Co. Ltd now owns 2,159 shares of the company’s stock valued at $422,000 after buying an additional 1,519 shares in the last quarter. Finally, D.A. Davidson & CO. lifted its holdings in shares of Zoetis by 4.3% during the 3rd quarter. D.A. Davidson & CO. now owns 25,979 shares of the company’s stock valued at $5,076,000 after acquiring an additional 1,062 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Morgan Stanley lowered their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Stifel Nicolaus lowered their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Barclays increased their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Finally, Piper Sandler boosted their price objective on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $215.90.

Insider Transactions at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,862 shares of company stock valued at $312,254 over the last quarter. Company insiders own 0.16% of the company’s stock.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.